LMLorenza Matarazzo

Lorenza Matarazzo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lorenza Matarazzo has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cytomegalovirus‐RNA Accurately Identifies Clinically Significant Infection Needing Preemptive Therapy in Liver Transplanted Children: A Proof‐of‐Concept Study

    by Emanuele Nicastro, Eleonora Severi, Ilaria Passera, Michele Totaro, Lorenza Matarazzo, Laura Fornataro, Francesco Morotti, Alessandra Tebaldi, Ezio Bonanomi, Michela Bravi, et al.

    Preemptive therapy (PET) is safe and effective in controlling Cytomegalovirus (CMV) infection after pediatric liver transplantation (LT) and allows to observe the kinetics of quantitative CMV‐DNA viral load till it reaches the treatment thresholds. While early detection of low‐to‐moderate CMV‐DNA levels may not indicate active viral replication, awaiting the viral load to exceed the treatment threshold may lead to viremic breakthroughs and CMV disease. We assessed the capacity of quantitative CMV‐RNA (UL21.5 mRNA) to identify active viral replication and its accuracy in identifying clinically significant CMV infection (csCMVi) needing PET in LT children. One‐hundred and forty‐four comparative quantitative CMV‐RNA and CMV‐DNA determinations were obtained from 12 children followed prospectically for 6 months after LT. Of 52 CMV‐DNA‐positive specimens, 17 (32%) were also CMV‐RNA‐positive, while CMV‐RNA was undetectable in CMV‐DNA‐negative specimens. All children with csCMVi had early detectable CMV‐RNA, peaking simultaneously to CMV‐DNA (median CMV‐DNA: 65 906 cp/mL; median CMV‐RNA: 767 cp/mL); conversely, none of those with persistently low DNAemia proved CMV‐RNA‐positive. In this first pilot study, CMV‐RNA had 100% sensitivity and specificity in identifying children needing PET after pediatric LT. The early detection of CMV‐RNA marks significant CMV infection/reactivation, thus allowing to avoid unnecessary antiviral treatment.


  • Clinical features, histology and outcome of pediatric porto-sinusoidal vascular disease

    by Angelo Di Giorgio, Lorenza Matarazzo, Aurelio Sonzogni, Emanuele Nicastro, Andrea Pietrobattista, Mara Cananzi, Paola Gaio, Marco Sciveres, Grazia Di Leo, Raffaele Iorio, et al.

  • Paediatric porto‐sinusoidal vascular disease: Two different clinical phenotypes with subtle histological differences

    by Angelo Di Giorgio, Lorenza Matarazzo, Aurelio Sonzogni, Emanuele Nicastro, Andrea Pietrobattista, Mara Cananzi, Paola Gaio, Marco Sciveres, Grazia Di Leo, Raffaele Iorio, et al.

    Background and Aims: In paediatrics, porto‐sinusoidal vascular disease (PSVD) is relatively unknown and probably underdiagnosed. We aimed to describe clinical phenotypes, histology and outcome of children diagnosed with PSVD.Methods: Retrospective multicentre study of children diagnosed with PSVD. Diagnosis of PSVD was based on histopathology reports; liver specimens were re‐evaluated by two expert liver pathologists.Results: Sixty two children diagnosed with PSVD (M/F = 36/26, median age 6.6 years, range 3.3–10.6), from 7 centres, were included. Thirty‐six presented with non‐cirrhotic portal hypertension, PH, (PH‐PSVD Group = 58%) while 26 had a liver biopsy because of chronic elevation of transaminases without PH (noPH‐PSVD Group = 42%). On histology review, the two groups differed for the prevalence of obliterative portal venopathy (more prevalent in PH‐PSVD, p = 0.005), and hypervascularised portal tracts (more common in noPH‐PSVD, p = 0.039), the other histological changes were equally distributed. At multivariate analysis, platelet count ≤185 000/mm3 was the only independent determinant of PH (p < 0.001). After a median follow‐up of 7 years (range 3.0–11.2), in PH‐PSVD group 3/36 (8%) required TIPS placement, 5/36 (14%) developed pulmonary vascular complications of PH, and 7/36 (19%) required liver transplantation. In noPH‐PSVD none progressed to PH nor had complications.Conclusions: Paediatric patients with PSVD present with two different clinical phenotypes, one characterised by PH and one by chronic elevation of transaminases without PH. PSVD should be included among the conditions causing isolated hypertransaminasaemia. On histology, the differences between the two groups are subtle. Medium‐term outcome is favourable in patients without PH; progression of the disease is observed in those with PH.


  • MYO5B Gene Mutations

    by Lorenza Matarazzo, Anna Monica Bianco, Emmanouil Athanasakis, Marco Serveres, Paola Francalanci, Giovanna Cenacchi, Giuseppe Maggiore, Adamo Pio D'ADamo, Marco Sciveres

    Objectives: Progressive familial intrahepatic cholestasis is an expanding group of autosomal recessive intrahepatic cholestatic disorders. Recently, next‐generation sequencing allowed identifying new genes responsible for new specific disorders. Two biochemical phenotypes have been identified according to gamma‐glutamyltransferase (GGT) activity. Mutations of the myosin 5B gene (MYO5B) are known to cause microvillus inclusion disease. Recently, different mutations in MYO5B gene have been reported in patients with low‐GGT cholestasis.Methods: A multicenter retrospective and prospective study was conducted in 32 children with cryptogenic intrahepatic cholestasis. Clinical, biochemical, histological, and treatment data were analyzed in these patients. DNA from peripheral blood was extracted, and all patients were studied by whole exome sequencing followed by Sanger sequencing.Results: Six patients out of 32 had mutations in the MYO5B gene. Of these six patients, the median age at disease onset was 0.8 years, and the median length of follow‐up was 4.2 years. The most common signs were pruritus, poor growth, hepatomegaly, jaundice, and hypocholic stools. Two patients also showed intestinal involvement. Transaminases and conjugated bilirubin were moderately increased, serum bile acids elevated, and GGT persistently normal. At anti‐Myo5B immunostaining, performed in liver biopsy of two patients, coarse granules were evident within the cytoplasm of hepatocytes while bile salt export pump was normally expressed at the canalicular membrane. Six variants in homozygosity or compound heterozygosity in the MYO5B gene were identified, and three of them have never been described before. All nucleotide alterations were located on the myosin motor domain except one missense variant found in the isoleucine‐glutamine calmodulin‐binding motif.Conclusions: We identified causative mutations in MYO5B in 18.7% of a selected cohort of patients with intrahepatic cholestasis confirming a relevant role for the MYO5B gene in low‐GGT cholestasis.


  • Open Access

    Successful fenofibrate therapy for severe and persistent hypertriglyceridemia in a boy with cirrhosis and glycerol‐3‐phosphate dehydrogenase 1 deficiency

    by Lorenza Matarazzo, Valentina Ragnoni, Cristina Malaventura, Alberta Leon, Davide Colavito, Giovanni Battista Vigna, Giovanni Lanza, Aurelio Sonzogni, Giuseppe Maggiore

    Glycerol‐3‐phosphate dehydrogenase 1 deficiency is a rare autosomal recessive disorder caused by mutations in the GPD1 gene (GPD1; OMIM*138420). Very few cases are reported in literature. It usually manifests in early infancy with transient hypertriglyceridemia, hepatomegaly, steatosis, and fibrosis. We report the case of a 16‐year‐old boy followed since the age of 1 year for hepatomegaly, elevated liver enzymes, and persistent hypertriglyceridemia. Abdominal ultrasound showed diffuse liver echogenicity and liver biopsy disclosed cirrhosis with micro and macrovesicular steatosis. Next‐generation sequencing for metabolic and genetic liver diseases was conducted with the identification of the homozygous mutation c.895G>A in GPD1 gene resulting in the aminocidic substitution p.G299R. Considering the persistent and progressive increase of plasma triglycerides, fenofibrate treatment was started at 15 years of age allowing triglyceride level reduction in the following 1‐year follow‐up.


  • B-cell depletion induces prolonged remission in patients with giant cell hepatitis and autoimmune hemolytic anemia

    by Lorenza Matarazzo, Teresa Di Chio, Silvia Nastasio, Alberto Tommasini, Alessando Ventura, Giuseppe Maggiore


  • Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine

    by Silvia Nastasio, Marco Sciveres, Lorenza Matarazzo, Cristina Malaventura, Francesco Cirillo, Silvia Riva, Giuseppe Maggiore


  • Open Access

    Wandering Liver, Wondering Doctors!

    by Lorenza Matarazzo, Martina Mazzocco, Anna Gioachin, Sylvie Tagliati, Cristina Malaventura, Giuseppe Maggiore


  • Open Access

    Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood

    by Emmanuel Gonzales, Lorenza Matarazzo, Stéphanie Franchi-Abella, Alain Dabadie, Joseph Cohen, Dalila Habes, Sophie Hillaire, Catherine Guettier, Anne-Marie Taburet, Anne Myara, et al.

    Oral cholic acid (CA) replacement has been shown to be an effective therapy in children with primary bile acid synthesis defects, which are rare and severe genetic liver diseases. To date there has been no report of the effects of this therapy in children reaching adulthood. The aim of the study was to evaluate the long-term effectiveness and safety of CA therapy. Fifteen patients with either 3β-hydroxy-Δ5-C27-steroid oxidoreductase (3β-HSD) (n = 13) or Δ4–3-oxosteroid 5β-reductase (Δ4–3-oxo-R) (n = 2) deficiency confirmed by mass spectrometry and gene sequencing received oral CA and were followed prospectively. The median age at last follow-up and the median time of follow-up with treatment were 24.3 years (range: 15.3–37.2) and 21.4 years (range: 14.6–24.1), respectively. At last evaluation, physical examination findings and blood laboratory test results were normal in all patients. Liver sonograms were normal in most patients. Mean daily CA dose was 6.9 mg/kg of body weight. Mass spectrometry analysis of urine showed that excretion of the atypical metabolites remained low or traces in amount with CA therapy. Liver fibrosis scored in liver biopsies or assessed by elastography in 14 patients, after 10 to 24 years with CA therapy, showed a marked improvement with disappearance of cirrhosis (median score < F1; range: F0-F2). CA was well tolerated in all patients, including five women having 10 uneventful pregnancies during treatment. Oral CA therapy is a safe and effective long-term treatment of 3β-HSD and Δ4–3-oxo-R deficiencies and allows affected children to reach adulthood in good health condition without the need for a liver transplantation.